Immune Design CS
(IMDZ)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2013 | 12-2012 | |
| Sales | 1,599 | 2,960 |
| Cost of Goods | 669 | 1,518 |
| Gross Profit | 930 | 1,442 |
| Operating Expenses | 16,656 | 12,835 |
| Operating Income | -15,057 | -10,875 |
| Other Income | -918 | 35 |
| Pre-tax Income | -15,975 | -10,840 |
| Net Income Continuous | -15,975 | -10,840 |
| Net Income | $-15,975 | $-10,840 |
| EPS Basic Total Ops | -43.48 | -30.43 |
| EPS Basic Continuous Ops | -43.48 | -30.43 |
| EPS Diluted Total Ops | -43.48 | -30.43 |
| EPS Diluted Continuous Ops | -43.48 | -30.43 |
| EPS Diluted Before Non-Recurring Items | -2.28 | N/A |
| EBITDA(a) | $-14,650 | $-10,327 |